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Objective: To describe the history of toxic epidermal necrolysis, before and after the original report by the
British dermatologist Alan Lyell in 1956.
Methods: Subjective expert choice of key advances in the comprehension of the nosology, classiﬁcation,
causality, and mechanisms of epidermal necrolysis (EN) over more than a century.
Results: Epidermolysis had been reported long before Lyell’s paper, but most cases had likely been
staphylococcal scalded skin syndrome in children. Concerning non-Staphylococcus EN, confusion with
erythema multiforme dissipated and its relation to StevenseJohnson syndrome was clariﬁed. Tremen-
dous advances were made in understanding the causes and mechanisms, with increased acceleration in
the last 10 years.
Conclusion: The next decade should be devoted to improve the prevention and management of a disease
that is the most terrible form of drug hypersensitivity.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.History of the disease: Nosology/classiﬁcation, and diagnosis
Original description of toxic epidermal necrolysis
The name “toxic epidermal necrolysis (TEN)”was introduced in 1956
by Lyell1 to describe the clinical disorder characterized by extensive
destruction of epidermis that resembled scalding. Since then, the
eponym Lyell’s syndrome becamewidely accepted. As acknowledged
later by Lyell,2 his original paper mixed three different disorders that
all had been already described more or less clearly.
Theﬁrst onewas rapidly identiﬁed as staphylococcal scalded skin
syndrome,3 and Lyell himself4 (Figure 1) contributed to the discov-
ery of the toxin responsible for a superﬁcial, subcorneal detachment
that is histologically very distinct from the deep necrolysis charac-
terizing TEN.5 This had been previously recognized and reported as
“neonatal pemphigus”6,7 or von Rittershain disease.8
The second is now labeled as generalized bullous ﬁxed drug
eruption (GBFDE),9 a disease characterized by necrolysis of full-
thickness epidermis on large well-demarcated blisters, which is
similar to that of TEN; however, it is distinct from TEN in the
absence or, if present, mildness of mucous membranes erosions,
usual relapses, as well as with mild differences in histopathology.d’Alembert, 92160 Antony,
iwanese Dermatological AssociatioPresent knowledge remains insufﬁcient to deﬁne the boundaries of
GBFDE versus TEN clearly.
The description of TEN had already been provided by some
predecessors to Lyell under different denominations: “unusual
bullous eruption” (Lang andWalker in 195610), “erythrodermawith
epidermolysis” (Debré et al 193911).Erythema multiforme, StevenseJohnson syndrome, and related
diseases: History and confusion
The initial description of erythema exudativum multiforme is
attributed to von Hebra.12 I was not able to consult von Hebra’s
original reports but from photographic pictures of Hebra’s draw-
ings it seemed to encompass many skin diseases with a circinate
pattern, of which some would probably be given a variety of other
denominations today [e.g., erythema annulare, pyoderma gan-
grenosum, subacute lupus erythematosus (LE), Sweet’s syndrome].
Rendu in 1916,13 Fiessinger and Rendu in 191714 described a
mucocutaneous eruption without clear cause that was later on
reported as FiessingereRendu syndrome or plurioriﬁcial erosive
ectodermosis, and retrospectively seems very similar to the two
cases described in 1922 by Stevens and Johnson.15 In Germany
Fuchs syndrome is used to describe a variant of erythema multi-
forme, and this syndrome mainly involves the mucosal surfaces. As
the skin may be completely unaffected, it is an underrecognized
diagnosis and often difﬁcult to conﬁrm.16n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Alan Lyell speaking at the ﬁrst International Symposium on TEN, Créteil
1985.
Table 1 SCAR study classiﬁcation of EMM and Epidermal necrolysis.
Classiﬁcation Type of lesions Distribution % BSA
eroded
EMMa Typical targets Acral d
SJSa Spots  atypical targets Widespread <10
Overlap SJSeTEN Spots  atypical targets Widespread S10 to 30
TEN with spots Spots  atypical targets Widespread S30
TEN without spotsb Diffuse erythema, no spot
or target
Widespread S30
BSA ¼ body surface area; SCAR study ¼ Severe Cutaneous Adverse Reactions study;
SJS ¼ StevenseJohnson syndrome; TEN ¼ toxic epidermal necrolysis.
a Some cases with discordant criteria (widespread typical targets or acral spots)
were classiﬁed as atypical EMM or atypical SJS, respectively
b Most cases of “TEN” without spots” had an alternative diagnosis of generalized
bullous ﬁxed drug eruption.
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“EM major (erythema multiforme major, EMM)” was proposed in
the early 1950s for separating the classical mild cutaneous syn-
drome, as described by Hebra (erythema multiforme minor), from
the usually more severe syndrome, with marked mucosal damage,
as described by Stevens and Johnson, Fiessinger and Rendu, or
Fuchs (all grouped under erythema multiforme major or majus).17
Because many physicians had observed the progression of cases
from a phenotype of StevenseJohnson syndrome (SJS) to a
phenotype of TEN,18,19 TEN was included for years in an “EM
spectrum”19 or in an even larger “mucocutaneous syndrome.”20
Attempts to clarify the confusion
Several facts were challenging the concept of the EMeSJSeTEN
spectrum. First, the individual lesions that preceded detachment of
epidermis were not suspected of being EM by Stevens and Johnson.
In clinical reports of TEN, early lesions were clearly reported as “red
or purple macules, often brown, occasionally purpuric, sometimes
looking like ‘targets’ close to EM.”21 Second, it was difﬁcult to
explain why “EM is often provoked by herpes simplex infection,
whereas I know of no evidence that this provokes TEN, if at all”
(Lyell19).
A ﬁrst proposal to split the “EM spectrum” was done by Ruiz-
Maldonado, a Mexican dermatologist who proposed the classiﬁ-
cation of acute disseminated epidermal necrosis (ADEN) types 1, 2,
and 3 for what we would call today SJS, overlap SJSeTEN, and TEN,
respectively. ADEN was ipso facto separated from EM.22
In 1987, as a preliminary step to a large case-control study of the
risk factors for EMM, SJS, and TEN, an international group of in-
vestigators had to agree on deﬁnitions and classiﬁcation criteria.
After reviewing several hundred photographs of historical cases,
they proposed a classiﬁcation based on the individual pattern and
topographic distribution of the skin lesions andmaximum extent of
blisters/erosions (expressed as percentage of body surface area
involved).23
Implicit to this new classiﬁcation were the hypotheses that: (1)
EMM is different from SJS, and (2) SJS and TEN are only severity
variants of a single entity.
Both hypotheses were strongly supported by the results of the
case-control analyses done on 552 patients and 1720 controls and
showing that EMM differed from both SJS and TEN by de-
mographics, associated diseases, causes, and severity, and that SJS,TEN, and overlapping cases differed only by the extent of detach-
ment, and therefore severity.24 These results strongly suggested
that a “spectrum from EMM to TEN” does not exist, but rather that
there is on one hand a group of typical/atypical EMM and on the
other a real continuum from SJS toTEN. The simplest way to express
this continuumwould be the denomination of epidermal necrolysis
(EN) that is used in this review.
Current classiﬁcation
Most authors currently use the “Severe Cutaneous Adverse Re-
actions (SCAR) study” classiﬁcation,23 presented in Table 1.
Diagnosis criteria are based on expert consensus and were never
submitted to formal validation. These criteria are erosions of mu-
cous membrane on at least two different sites, “spots” or “atypical
targets,” skin blisters or erosions, skin pain, Nikolsky’s sign, and
detachment of large epidermal sheets. The diagnosis is probable if
three or more of the aforementioned criteria are present, deﬁnite if
conﬁrmed by unequivocal clinical photographs, and/or biopsy. The
typical histology pattern shows extensive apoptosis of keratino-
cytes on the full thickness of the epidermis and mild interface
dermatitis. Negative direct immunoﬂuorescence ﬁndings are
important in case of ambiguous histology.
Differential diagnoses are listed in Table 2, and
Table 31,3,9,11e15,18,22,23,28,29,32,33,37,38,43e48,50,52,53,58e60,63e66 presents
the key dates and publications related to epidermal necrolysis.
Epidemiology
The best available evidence on the incidence of EN was provided by
studies done before the generalized use of current classiﬁcation.
There was obviously some room for ambiguity. For EMM, SJS, TEN,
altogether the ﬁgure was four cases/million/year in the United
States.25 In France, Germany, Italy, and Singapore, the incidence of
TEN was reported to be one case/million/year26,27 using disease
deﬁnitions encompassing what we would now call TEN (more than
30% detachment) and SJSeTEN overlap (10e29% detachment).
Concerning SJS, more recent data suggest an incidence that is about
equal to the total of TEN and SJSeTEN overlap.28 Taking all these
data into account, a ﬁgure of two cases/million inhabitants/year can
be considered highly plausible for EN in Europe. The incidence may
bemore elevated in other parts of theworld because of risks related
to ethnicity29 or to more frequent use of “highly associated” med-
ications (Africa).
Severity
The high mortality associated with TEN was recognized very early.
Actually the qualiﬁcation of “toxic” chosen by Lyell referred to the
Table 2 Main differential diagnoses of SJS/TEN.
Diagnosis Context Main clinical differences Pathology Causes
SSSS Infants, renal failure in adults No mucous membrane involvement Subcorneal detachment Staphylococcus toxins
AGEP Recent initiation of medicines Pustules Subcorneal pustules Medications a
Burns Unconsciousness Absence of “spot” or atypical targets Epidermis involved on variable
thickness
Thermal or chemical
aGVHDb Bone marrow transplantation Slower progression, gut and liver
involved
May be very close to that of TEN Alloimmunity
LEb SLE or SCLE Slower progression, photo
distribution
May be very close to that of TEN Autoimmunity
Paraneoplastic pemphigus Lymphoma Slower progression, severe mouth
lesions
Acantholysis, positive DIF Ab-mediated
autoimmunity
LABD, drug induced Recent initiation of medicines Some tense blisters Subepidermal blister, no necrosis,
pos. DIF
Medicationsc
E(E)MM Children, young adults, frequent
recurrences
Typical targets, no conﬂuence Less necrosis, more inﬁltrates Infections, idiopathic
AGEP ¼ acute generalized exanthematous pustulosis; aGVHD ¼ acute graft-versus-host disease; E(E)MM ¼ erythema (exsudativum) multiforme majus; LE ¼ lupus ery-
thematosus; LABD ¼ linear IgA bullous disease; pos. DIF ¼ positive DIF; SCLE¼subacute cutaneous lupus erythematosus; SLE ¼ systemic lupus erythematosus;
SSSS ¼ staphylococcal scalded skin syndrome; SJS ¼ StevenseJohnson syndrome; TEN ¼ toxic epidermal necrolysis.
a Frequently responsible drugs: amoxicillin, diltiazem, hydroxychloroquine, terbinaﬁne
b It is not yet clear whether aGVHD should be considered a cause of EN or a differential
c Frequently responsible drugs: vancomycin, diclofenac, several antibiotics.
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mechanisms as it was too often believed later. For years, SJS was
considered much more benign, probably in large part because of
confusion with EMM. A recent cohort study that included 460 pa-
tients with EN observed an overall disease-related mortality of 30%
at 90 days after onset. The death rates were 20%, 30%, and 50% for
subgroups of SJS, overlap, and TEN, respectively.28 In addition to
very high mortality, EN is the cause of nearly constant sequelae,
occasionally progressing and often invalidating.Table 3 Key dates and publications related to epidermal necrolysis.
Date Author(s) Co
1866 von Hebra Ery
1916, 1917 Rendu, Fiessinger and Rendu Mu
1922 Stevens and Johnson Ste
1939 Debré et al Bu
1956 Lyell To
1968 Bergoend H et al Hig
1968, 1970 Billingham and Streilein, Streilein and Billingham TE
1970 Mellish and Glasgow Sta
1972 Peck et al Hu
1972 Kauppinen Dr
1985 Ruiz-Maldonado AD
1985 Revuz et al Fir
1985 Lyell A (Créteil meeting) Th
1986 Roujeau et al Mi
1987 SCAR study group Ini
1990 Roujeau and Revuz Ac
1993 Correia et al Stu
1993 Bastuji-Garin et al Co
1995e2002 Pichler et al Dr
1995 Roujeau et al Re
1998 Wolkenstein et al Fir
2000 Bastuji-Garin et al SC
2002 Nassif et al Dr
2004 Chung et al Ca
2005 Hung et al All
2008 Mockenhaupt et al Eu
2008 Chung et al Gr
2011 Ko et al Re
2011 Genin et al GW
2012 Wei et al Dir
2012 Chen et al Era
2013 Sekula et al SJS
ADEN ¼ acute disseminated epidermal necrosis; EN ¼ epidermal necrolysis; GWA
concept ¼ pharmoco-immune concept; RCT ¼ randomized controlled trial; SCAR study
TCR ¼ T-cell receptor; TEN ¼ toxic epidermal necrolysis.Evolution of concepts on causality
The concept that medications were a frequent, if not the only, cause
of TEN was rapidly accepted by the medical community. may be
too quickly in the opinion of Lyell.19 Strong evidence of such cau-
sality (and also of relationship between SJS and TEN) was provided
by several mass campaigns of prevention of infectious diseases by
long-acting sulfonamides, as these resulted in “epidemics” of SJS
and TEN.18,30ncept Refs
thema exsudativum multiforme 12
ltioriﬁcial ectodermosis 13,14
venseJohnson syndrome 15
llous erythroderma with epidermolysis 11
xic epidermal necrolysis 1
h risk of long-acting sulfonamides 18
N and a graft-versus-host model in hamsters 37,38
phylococcal scalded skin syndrome 3
man graft-versus-host reaction as a cause of TEN 39
ug rechallenge often negative in SJS and TEN 9
EN types 1, 2, and 3 22
st international meeting on TEN, Créteil, France d
e Jackpot hypothesis d
ld links between HLA and TEN 58
tiation of multinational case-control study on EN d
ute skin failure 64
dying T cells in blister ﬂuid of TEN 43
nsensus deﬁnition of EEMM, SJS, and TEN 23
ug-speciﬁc T cell clones, p-i concept 44e47
sults from ﬁrst case-control study of drug risks in EN 32
st RCT in TEN (thalidomide proved deleterious) 65
ORTEN, a prognosis score allowing comparisons between series 66
ug-speciﬁc cytotoxic cells in blister ﬂuid of TEN 48
rbamazepine (CBZ)-related TEN and HLA-B*15:02 29
opurinol-related TEN and HLA-B*58:01 59
roSCAR case-control study of SJS/TEN 33
anulysin as the key cytokine in necrolysis 50
stricted TCR needed for CBZ-related SJS/TEN 52
AS on a large European series of SJS/TEN cases 60
ect noncovalent link between CBZ and HLA-B1502 53
dication of CBZ-induced TEN from Taiwan 63
/TEN even more severe than suspected 28
S ¼ genome-wide association studies; HLA ¼ human leukocyte antigen; p-i
¼ Severe Cutaneous Adverse Reactions study; SJS ¼ StevenseJohnson syndrome;
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suspected in the two original cases published by Stevens and
Johnson.15 However, only one of the four original cases was re-
ported by Lyell.1
In 1990, I contributed a review on SJS and TEN stating that
“Drugs are the most important, if not the only, cause of TEN .
Infections are well-recognized causes of SJS but not of TEN.”31 Both
statements were erroneous: the hypothesis of different causes for
SJS and TEN was wrong and so is the suggestion that TEN had no
other cause than drugs.
The results of the SCAR case-control study clearly indicated that
the “etiologic fraction” for “associated medications” was very
similar for SJS, overlap SJSeTEN, and TEN and around 0.65 in all
three groups.24,32 Because the etiologic fractionwas calculated only
for drugs with a statistically signiﬁcant association, it was under-
estimated by lack of statistical power. Further experience on larger
numbers of cases conﬁrmed the existence of lowpercentage of cases
without any exposure to medications (2e3%) and a larger number
(10e15%) of cases exposed to several drugs that all were unlikely the
cause. In 20e25% of cases, one or several medications were possibly
the cause without any deﬁnite certainty.33 In conclusion, no more
than 70e80% of cases are drug induced and the percentages are
similar for SJS, TEN, and overlaps.34 The percentage of “idiopathic
cases” is probably higher in children. Up to now only a very low
proportion of cases of EN (z1%) had an established nondrug cause.
These causes include acute graft-versus-host-disease (GVHD), some
variants of acute LE,35 and infections. Infection-related EN was
especially demonstrated with Mycoplasma pneumoniae36 but other
agents were also suspected (Klebsiella pneumoniae, viruses). Over
dosages of methotrexate or colchicine may also induce damages of
skin and mucous membrane that closely resemble EN.
Progress on comprehension of mechanisms
In early reports, the mechanisms leading to EN appeared very
mysterious. Histological slides of skin lesions actually evidenced
the total destruction of the epidermis upon a “silent dermis” with a
very mild cell inﬁltrate, no lesion of vessels, no deposits of immu-
noglobulins (Ig) or complement.
Some important steps in the advancement of knowledge are
summarized below.
Resemblance to GVHD
The ﬁrst animal model resulting in necrolysis of epithelial cell was
established byBillinghamand Streilein, two famous immunologists,
in 1968 and 1970.37,38 The EN developed around a site of local GVHD
in a complexmodel of cutaneous GVHD, at a timewhen the key role
of dendritic cells was still unknown. In this model, an unidentiﬁed
substance present in the plasma was able to cause epidermolysis.
In 1972, TEN was reported as a possible expression of acute
GVHD in humans.39
More recently, a Japanese team developed a mouse model of
GVHD in transgenic mice expressing OVA in keratinocytes and
developing epidermolysis after the transfer of OVA-speciﬁc cyto-
toxic T cells.40 The development of epidermolysis needed some
immunosuppression and implied inactivation of regulatory cells.41
Focus on blister ﬂuid
The ﬁrst attempts to study T cells at the site of lesions used immu-
nolabeling techniques and extraction of T cells from trypsinized
sheets of necrotic epidermis. Very few cells were obtained and
viabilitywas poor.42 Tremendous progressesweremade possible by
studying cells present in the blister as ﬁrst done by Osvaldo Correiaet al in Portugal.43 Many advances were made by studying this
blister ﬂuid and characterizing the cells present in this ﬂuid.
Drug-speciﬁc T cells
In the last 20 years, the key role of drug-speciﬁc T cells in drug
allergywas deﬁnitely demonstrated by the establishment of human
T-cell clones, derived from the blood lymphocytes or from skin
lesions of patients with a variety of reactions. T-cell clones
demonstrated that drugs can be recognized by human T cells and
suggested original pathways of activation. Clones have been ob-
tained with most medications that induce allergic reactions in
humans, including penicillin G, amoxicillin, sulfamethoxazole,
phenobarbital, carbamazepine (CBZ), and lamotrigine. They were
often of both CD4 and CD8 phenotypes, whatever the original type
of eruption had been.44e47
TEN drug-speciﬁc T cells were found in the blister ﬂuid of pa-
tients with TEN, which were reported to kill autologous cells
(lymphocytes and keratinocytes) in a major histocompatibility
complex (MHC) class I-restricted pathway.48 In addition to the
drug-speciﬁc CD8 memory cells, natural killer (NK) cells and NK T
cells also contribute to apoptosis of epithelial cells.49e51
Pharmoco-immune concept
With many drugs, a very original observation was that the drug
could be presented to the T-cell receptor (TCR) and activate speciﬁc
clone without prior processing by the antigen-presenting cell and
through a noncovalent binding to the MHC or its embedded pep-
tide.46 Because the noncovalent binding is reminiscent of the
pharmacological interaction between a drug and its receptor, the
denomination of pharmoco-immune concept has been proposed.47
This concept is supported by recent ﬁndings about direct links of
medications (e.g., CBZ) with both human leukocyte antigen (HLA)
and TCR.52,53
Fas ligand
It was generally agreed that therewere too few cytotoxic cells in the
lesions of EN to explain the extent of epidermolysis and that soluble
death mediators were also involved. A succession of cytokines had
been suspected, such as tumor necrosis factor-a (TNF-a), perforin,
granzyme B, but the most popular for more than 10 years has been
Fas ligand.54 Activated keratinocytes express Fas-L and epidermal
sheets of patients with EN-killed Jurkat cells (a lymphocyte cell line
that is exquisitely sensitive to Fas-L-induced apoptosis). Human Ig
inhibited the apoptosis of Jurkat cells. These ﬁndings were exag-
gerated as: (1) “collective suicide” of keratinocytes through Fas-Le
Fas interactions (even though no evidence was provided that Fas L
killed keratinocytes), and (2) possible inhibition of apoptosis of
keratinocytes by human Ig (even though evidence points that the
effect was only on Jurkat cells). Further studies have demonstrated
the absence or very low impact of Fas-L on keratinocytes and no
beneﬁt from using high-dose human Ig (intravenous Ig) to treat
patients with EN.55
Regulatory cells
Clinicians noticed that patients developing EN suffered more often
than controls from conditions that impaired immune response,
advanced malignancy, autoimmune diseases, and long-term ther-
apy with corticosteroids.33,56 In Azukizawa’s mouse model, devel-
opment of EN needed prior inactivation of regulatory cells.41
Studies in humans strongly suggested that a deep depression in
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stage of EN.57 Further studies are deﬁnitely needed on this topic.
Granulysin
In 2008, a key paper50 reported the work of the team directed by
W.H. Chung and S.I. Hung demonstrating that granulysin was
actually the main cytokine responsible for the apoptosis of
epithelial cells in EN. Not only was granulysin present in the blisters
at concentrations 100 times more elevated than perforin or gran-
zyme B, but it also killed target cells in vitro and induced blisters
with a necrotic roof when injected in the skin of normal mice at the
concentration observed in blisters. Fas-L was detected in very low
concentrations without any detectable effect. Granulysin was
released by drug-speciﬁc cytotoxic CD8 T cells and NK cells. Mac-
rophages often recruited in the lesions are also able to produce
granulysin. These ﬁndings have several tremendous consequences:
(1) clearly they demonstrate that the many other cytokines previ-
ously considered as contributing to EN (e.g., TNF-a, Fas-L, TRAIL,
Tweak) have a mild and likely accessory role; and (2) they point to
inhibiting the release and/or the effects of granulysin as the main
goal in an emergency treatment of EN.
HLA associations
A mild association of EN with HLA had been reported more than 25
years ago58 but since 2004 several studies have shown strong and
complete associations of HLA-B*15:02 allele with CBZ-induced
EN29 and of HLA-B*58:01 with allopurinol-induced EN.59 Associ-
ated alleles show very different frequency distribution around the
world being frequent in some parts of Asia and less frequent or rare
in Europe.60 That association appeared both drug speciﬁc and
phenotype speciﬁc and related to ethnicity. HLA associations are a
ﬁeld of intense and productive research. A direct link between the
medication and the relevant HLA molecule was demonstrated for
CBZ53 and abacavir61 as suggested years ago for penicillin.62 The
demonstration that patients suffering from EN also have a
restricted use of speciﬁc clonotypes of the TCR52 is a major progress
to explain why a minority of persons harboring the HLA-B*15:02
phenotype developed EN when taking CBZ. Furthermore, the
prevalence of CBZ-related EN was largely decreased from Taiwan,
where it had been the primary cause, by testing for HLA-B*15:02
before prescription in recent years.63
The Jackpot hypothesis
The “Jackpot” hypothesis was proposed by Lyell in 1985 during a
discussion about the mechanisms of EN in the ﬁrst international
symposium on TEN. The disease is so rare that its occurrence needs
the conjunction of several rare risk factors, including intake of
“strongly associated” medication, adequate HLA, and certainly a
few others such as adequate TCR variant and perturbation of reg-
ulatory cells.
The future
Looking back to the history of EN, it appears that in the past decades
the knowledge about EN had improved tremendously, slowly
initially but more rapidly in the last few years. Most of these more
recent advances were provided by a leading Taiwanese team.
With the important exception of HLA testing for CBZ in Asia,
progresses in knowledge have not yet resulted in major beneﬁts for
the victims of what is the most severe form of adverse reaction to
drugs.The existence and development of international networks of
researchers (e.g., RegiSCAR, J-SCAR, Asian-SCAR), active patient
associations, and reference centers for treatment, provide a basis
for new progresses and especially for translating progresses from
laboratories to patient care.
Decreasing the incidence (detection of patients “at risk,” re-
striction of use of “strongly associated” medicines), earlier diag-
nosis and better care (reference centers, speciﬁc treatments),
prevention and treatment of sequelae should be priorities for re-
searchers and clinicians. No speciﬁc treatment has been proven to
be effective until now. Therefore, increased focus is needed on
agents inhibiting the release and/or blocking the effects of
granulysin.
More implication of pharmaceutical companies and regulatory
agencies in promoting research and helping the victims is deﬁnitely
needed to decrease the burden of EN on public health.
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